{"id":"NCT00678418","sponsor":"Alkermes, Inc.","briefTitle":"ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","officialTitle":"Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-10","completion":"2010-11","firstPosted":"2008-05-15","resultsPosted":"2011-01-21","lastUpdate":"2017-02-10"},"enrollment":250,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opiate Dependence"],"interventions":[{"type":"DRUG","name":"VIVITROL® 380 mg","otherNames":["Naltrexone for extended-release injectable suspension","Medisorb® naltrexone"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"VIVITROL® 380 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 multi-center trial designed to evaluate the clinical efficacy and safety of VIVITROL® (Medisorb® naltrexone 380 mg) versus placebo when administered to adults upon discharge from inpatient treatment for opioid dependence.\n\nThe study was conducted in 2 parts, Part A and Part B. The clinical portion of both parts has completed. Results for Part B are not yet available.","primaryOutcome":{"measure":"Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)","timeFrame":"20 weeks","effectByArm":[{"arm":"VIVITROL® 380 mg","deltaMin":90,"sd":40.1},{"arm":"Placebo","deltaMin":35,"sd":43.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":14},"locations":{"siteCount":1,"countries":["Russia"]},"refs":{"pmids":["23701526","25901451","23036218","40342086","22945623","21529928"],"seeAlso":["http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60358-9/fulltext"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Gamma-glutamyl transferase increased","Nasopharyngitis","Influenza"]}}